MENU

April 9, 2022

Junshi Biosciences and Coherus Present Results of Phase 3 Study of Toripalimab in First Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at 2022 AACR Annual Meeting

– Toripalimab plus chemotherapy provided superior progression free survival, overall survival, overall response rate and duration of response compared to chemotherapy alone – SHANGHAI, China, and REDWOOD CITY, Calif., April 09, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi

Read More ➜

Covid-19 (April 8): 14,944 new cases, 31 fatalities

Published by Malaysiakini (English) COVID-19 | The Health Ministry reported 14,944 new Covid-19 infections yesterday, bringing the cumulative cases to 4,307,529. It also reported 31 new fatalities, which put the death toll at 35,259. Active cases stood at 158,440, down

Read More ➜

Recent News

ADVERTISMENT